SCHEMBL9856580

SCHEMBL9856580

Cc1cccc(C(F)(F)F)c1CC(CCN(C)C)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.43
HRH1 P35367 4/20 0.43
SLC6A4 P31645 4/20 0.41
HRH3 Q9Y5N1 1/20 0.41
SLC6A9 P48067 1/20 0.40
CYP2D6 P10635 3/20 0.36
CHRM2 P08172 3/20 0.36
SLC6A2 P23975 3/20 0.36
CHRM4 P08173 2/20 0.36
CHRM5 P08912 2/20 0.36
ADRA2A P08913 2/20 0.36
CHRM1 P11229 2/20 0.36
ADRA2B P18089 2/20 0.36
CHRM3 P20309 2/20 0.36
HRH2 P25021 2/20 0.36
HTR2C P28335 2/20 0.36
ADRA1A P35348 2/20 0.36
OPRM1 P35372 2/20 0.36
DRD3 P35462 2/20 0.36
HTR2B P41595 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9856705 0.81 HTR2A (0.47) HTR2AHRH1SLC6A4HRH3SLC6A9
SCHEMBL9857086 0.75 HTR2A (0.53) HTR2AHRH1SLC6A4CYP2D6CHRM2
SCHEMBL9856736 0.75 HTR2A (0.46) HTR2AHRH1SLC6A4HRH3SLC6A9
SCHEMBL9857281 0.74 HRH1 (0.51) HTR2AHRH1SLC6A4HRH3CYP2D6
SCHEMBL9857350 0.73 SLC6A9 (0.67) HTR2AHRH1SLC6A4HRH3SLC6A9
SCHEMBL9856509 0.73 HTR2A (0.51) HTR2AHRH1SLC6A4HRH3SLC6A9
SCHEMBL9857222 0.71 HTR2A (0.49) HTR2AHRH1SLC6A4HRH3SLC6A9
SCHEMBL23841329 0.71 P2RX7 (0.39) HTR2ASLC6A4SLC6A2HTR2CHTR2B
SCHEMBL10597164 0.70 HTR2A (0.44) HTR2AHRH1SLC6A4HRH3SLC6A9
SCHEMBL9856881 0.69 SLC6A9 (0.43) HTR2AHRH1SLC6A4HRH3SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4996235-A Selectively inhibiting the uptake of serotonin and norepinephrine ELI LILLY AND COMPANY (US) 1991-02-26 US disclosed
EP-0318233-A2 Improvements in or relating to serotonin and norepinephrine uptake inhibitors ELI LILLY AND COMPANY (US) 1989-05-31 EP disclosed